Taysha Gene Therapies Inc (NASDAQ: TSHA) is 47.46% higher on its value in year-to-date trading and has touched a low of $1.19 and a high of $4.32 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TSHA stock was last observed hovering at around $3.08 in the last trading session, with the day’s loss setting it -0.47%.
Currently trading at $2.61, the stock is 16.18% and 26.04% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.44 million and changing -15.26% at the moment leaves the stock 6.27% off its SMA200. TSHA registered 41.85% gain for a year compared to 6-month loss of -29.08%. The firm has a 50-day simple moving average (SMA 50) of $2.0592 and a 200-day simple moving average (SMA200) of $2.452525.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 70.59% gain in the last 1 month and extending the period to 3 months gives it a 26.09%, and is -9.69% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.01% over the week and 14.69% over the month.
Taysha Gene Therapies Inc (TSHA) has around 52 employees, a market worth around $534.91M and $9.91M in sales. Profit margin for the company is -229.67%. Distance from 52-week low is 119.33% and -39.58% from its 52-week high. The company has generated returns on investments over the last 12 months (-15.23%).
with sales reaching $2.05M over the same period.The EPS is expected to grow by 61.46% this year, but quarterly earnings will post -46.63% year-over-year. Quarterly sales are estimated to shrink -43.04% in year-over-year returns.
Taysha Gene Therapies Inc (TSHA) Top Institutional Holders
155.0 institutions hold shares in Taysha Gene Therapies Inc (TSHA), with institutional investors hold 93.93% of the company’s shares. The shares outstanding are 204.94M, and float is at 153.61M with Short Float at 10.26%. Institutions hold 77.45% of the Float.
The top institutional shareholder in the company is FMR LLC with over 21.21 million shares valued at $47.51 million. The investor’s holdings represent 9.1722% of the TSHA Shares outstanding. As of 2024-06-30, the second largest holder is RTW INVESTMENTS, LP with 18.8 million shares valued at $42.11 million to account for 8.1299 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 18.65 million shares representing 8.0649% and valued at over $41.78 million, while BLACKROCK INC. holds 5.0778 of the shares totaling 11.74 million with a market value of $26.3 million.
Taysha Gene Therapies Inc (TSHA) Insider Activity
The most recent transaction is an insider purchase by Manning Paul B, the company’s 10% Owner. SEC filings show that Manning Paul B bought 1,333,333 shares of the company’s common stock on Jun 27 ’24 at a price of $2.25 per share for a total of $3.0 million. Following the purchase, the insider now owns 1.33 million shares.
